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The need to improve access to care and treatment for chronic hepatitis C virus (HCV) infection in resource-
limited settings is receiving increasing attention. Key priorities for scaling up HCV treatment and care include
reducing the cost of current and future treatment; simplifying the package of care; identifying opportunities to
shift specific tasks to nonspecialists to overcome human resource constraints; service integration with human
immunodeficiency virus (HIV) clinics, prison health services, and needle syringe and oral substitution therapy
programs; improving surveillance, monitoring, and research; encouraging patient and community engagement;
focusing specifically on the needs of vulnerable groups; and increasing financial and political commitment. Many
of these obstacles have been addressed in rolling out treatment for human immunodeficiency virus during the
last decade, and a number of lessons can be drawn to help improve access to HCV care.
Hepatitis C virus (HCV) infection is a growing public
health concern, with an estimated 170 million persons
infected globally and 350 000 deaths each year due to
hepatitis C–related liver disease [1]. In 2010 the World
Health Assembly adopted a resolution promoting in-
tegrated and cost-effective approaches to the prevention,
control, and management of viral hepatitis and noted
in particular the need to address hepatitis in the
context of the human immunodeficiency virus (HIV)
epidemic [2]. A number of countries in resource-limited
settings are providing treatment of HCV infection
through dedicated services with reasonable success
[3]. Generally, however, access to care remains limited,
particularly in poorer regions such as India and sub-Sa-
haran Africa [4].
Challenges to increasing access to treatment of HCV
infection in resource-limited settings include the high
cost and perceived complexity of treatment, side effects
that hamper adherence, long treatment duration, and
insufficient political commitment. Early efforts to
increase access to antiretroviral therapy (ART) for
HIV/AIDS in resource-limited settings were impeded
by similar challenges. We reflect on the experience of
scaling up access to ART during the last decade and
draw lessons for improving access to treatment and
care for persons with HCV.
A decade ago, treatment for persons living with
HIV/AIDS was unavailable in most developing coun-
tries, and there was debate about whether treatment
should be considered given the considerable challenges
faced [5]. Yet despite these early concerns, .6.6 million
persons are now receiving ART in the developing
world [6]. Several critical issues had to be confronted
before large-scale HIV treatment programs could be
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Table 1. Overcoming Barriers to Increasing Access to Treatment for Hepatitis C Virus Infection
Challenge Lessons From HIV/AIDS Action Points for HCV
Decrease cost of care
Ensure affordable, quality drugs WHO prequalification project provided
quality assurance mechanism for
generic antiretrovirals
Internationally recognized quality
assurance of generic/biosimilar
sources of drugs for HCV treatment
Several legal mechanisms have
proved successful for overcoming
patent barriers to stimulating
market competition
Prioritize policies that are proved to work
to reduce prices
Lower prices of originator drugs Lower prices of originator drugs
Reporting of treatment trends has
supported market forecasting
Develop international disease and treatment
surveillance for HCV
Dose optimization research is
encouraged to reduce cost of
drugs and reduce toxicity
Encourage dose optimization research
in HCV drug development
Simplification
Treatment guidelines WHO guidelines for management of
HIV/AIDS in resource-limited settings
published every 2–3 years
Develop international guidelines for management
of HCV in resource-limited settings
Drug regimens Trials undertaken to determine
optimal first-line regimens and
sequencing of future regimens;
fixed-dose combinations supported
treatment adherence and simplified
drug supply
Use in resource-limited settings should be
introduced as an important consideration
in HCV drug development and clinical
research, including development of
oral and fixed-dose combinations
Investigations Simple laboratory tests prioritized;
lack of laboratory tests should not
be a barrier to accessing treatment
Validate noninvasive techniques for assessment
of fibrosis in different populations and their
use in resource-limited settings; explore
use of facilities that have been developed for
HIV viral load testing for HCV virology
Research into simplified technologies
to support access to viral load and
genotyping (eg, dried blood spot and
point-of-care testing)
Evaluate potential for advances in HIV testing
to be applied to HCV, such as dried blood
spot and point-of-care tests
Cohort reporting Simplified monitoring integrated into
other national programs
Develop and evaluate indicators to enable
simplified monitoring tools
Task shifting
Task shifting guidelines WHO guidelines for task
shifting in HCV care
WHO guidelines for task
shifting in HCV care
Validation of different approaches Operational research, supported by
dedicated donor funding, has provided a
substantial evidence base to inform
future programming
Establish a prioritized operational
research agenda
Integration HIV diagnosis and treatment integrated
into other health services, such as
tuberculosis programs, STI care, and
antenatal care services
Evaluate the opportunities and
challenges of integrated vs vertical care
models for HCV diagnosis and treatment into
other services (HIV clinics, prison health
services, needle syringe and oral substitution
therapy programs)
Decentralization of services to primary
care level supports access and
retention in care
Develop models for integrating HCV care
into primary care
Research and surveillance High-quality epidemiological data
available from a wide variety of
locations and settings
Develop strategies to improve epidemiological
information, including genotype
Treatment monitoring and evaluation
built into some national programs
Consider monitoring and evaluation from
outset of program development
Low-technology solutions to investigations,
such as rapid testing and dried
blood spot testing
Consider applicability of advances made in
HIV research to HCV testing
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established. These are summarized in Table 1 and discussed
below.
REDUCING THE COST OF TREATMENT
Until mid-2000, ART cost about US $10 000 per patient per
year, and cost-effectiveness studies concluded that treatment
should not be prioritized [7]. This equation shifted as ge-
neric competition drove down the cost of treatment. This
was largely achieved thanks to significant political support by
a global alliance of civil society groups, and in particular
persons living with HIV/AIDS and health providers, non-
governmental organizations, and academics who worked
together as a global coalition for the rights of those with
HIV/AIDS to access treatment [5]. In 2001 a generics man-
ufacturer announced that triple therapy could be manufac-
tured for less than a dollar a day. This created a dynamic of
global market competition that drove down the price of
standard triple therapy from US $10 000 per patient per year
to almost US $60. Today, .80% of ART used in low-income
and middle-income countries is manufactured by Indian
generics firms [8].
Treatment of HCV infection is currently expensive in de-
veloping countries. Generic forms of ribavirin are available,
but pegylated interferon is patented in a number of low- and
middle-income countries, and overall costs of treatment are
high: a recent survey of 5 Asian countries reported that public
sector prices for a 48-week course of combination therapy
range from US $12 000 (Vietnam) to US $18 500 (Indonesia)
[9]. Several alternative sources of pegylated interferon have
recently been developed that have helped drive down the cost
of treatment. In Egypt, for example, a locally manufactured
biosimilar of pegylated interferon is produced [10], and
market competition has supported a 6-fold reduction in the
price of both originator and generic products: a 48-week
treatment course of pegylated interferon and ribavirin cur-
rently costs less than US $2000 in Egypt. Although com-
parative safety and efficacy data are limited for generic pegylated
interferon products, this nevertheless demonstrates that sub-
stantial price reductions are possible.
The World Health Organization (WHO) prequalification
scheme has played a critical role in the availability of affordable
antiretrovirals. This scheme is used by donors, implementing
organizations and many national programs to assure the quality
of generically produced antiretroviral drugs [11]. Similarly,
quality assurance of antivirals for HCV would give confidence to
donors, patients, and implementing organizations and would
allow developing countries to fast-track registration of generic
and biosimilar sources of antivirals for HCV. Existing bio-
similars of pegylated interferon are registered in only a few
Table 1 continued.
Challenge Lessons From HIV/AIDS Action Points for HCV
Patient and community engagement
Define roles Treatment literacy recognized early
on as a key part of patient engagement
Treatment literacy materials should be
developed to support patient
involvement in HCV care
Define incentives for
community engagement
Community health workers are an important
resource in treatment delivery, provided
they are adequately supported.
Engage patients and community
workers to promote adherence
to treatment and retention in care
Human rights
Monitor treatment access Reporting of numbers receiving treatment
disaggregated for specific vulnerable
groups
Ensure reporting of numbers receiving
treatment for specific vulnerable groups
Dedicated funding targeted to
vulnerable groups
Dedicated donor funding provided to
support treatment and care of
vulnerable groups
Encourage dedicated donor funding for
treatment and care of vulnerable groups;
increase HCV funding from AIDS donors,
such as GFATM or UNITAID
Financing
New funding mechanisms were
created to provide dedicated
funding for HIV/AIDS care in
resource-limited settings
The provision of specific, additional funding
to kick-start HCV treatment programs
Donor support needs to be matched
by political and financial support at
the national level
Political commitment from governments
with high burden of disease
Abbreviations: GFATM, Global Fund to Fight AIDS, Tuberculosis, and Malaria HCV; hepatitis C virus; HIV, human immunodeficiency virus; STI, sexually transmitted
infections; WHO, World Health Organization.
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countries and have not been quality assessed by WHO, although
guidance for the evaluation of biosimilars has been published
elsewhere [12].
Access to the newest generation of HCV medicines will be
critical, because these drugs have the potential to significantly
simplify treatment regimens and improve outcomes, offering
particular advantages for use in settings with limited facilities
[13, 14]. This will likely require concerted public and political
mobilization to pressure originator companies to reduce prices
and stimulate generic competition.
SIMPLIFYING THE MODEL OF CARE
HIV/AIDS care in developed countries is highly specialized.
Treatment initiation decisions are informed by CD4 count
and viral load, and treatment regimens are individualized
according to genotypic resistance pattern, clinical response,
side effects, and patient preference. More than 30 different
antiretroviral drugs are currently approved, allowing for
frequent medication adjustments.
In resource-limited settings, access to laboratory tests and
choice of medication are limited. Guidelines for the man-
agement of HIV/AIDS in resource-limited settings developed
by the WHO have helped to simplify management by speci-
fying only a limited selection of once- or twice-daily regimens
for first- and second-line therapy and recommending a lim-
ited set of laboratory tests that are desirable but not essential
[15]. The development of antiretroviral agents as fixed-dose
combination tablets has greatly helped to standardize and
simplify patient care. In addition, low-technology innovative
solutions to provision of essential tests have also been pur-
sued, such as dried blood spots for viral load testing [16].
Similar simplification is required to support HCV manage-
ment in poorly resourced settings. Current guidelines for treat-
ment of HCV infection are from developed country tertiary
care settings; include a variety of tests to initiate and guide care,
such as regular viral load monitoring; and involve a range of
antiviral and supplementary medications. Research to deter-
mine the need for each test will be important to make HCV
treatment feasible and cost-effective in resource-limited settings.
Recent innovations enabling noninvasive assessment of
liver fibrosis have important possible applications in HCV
management decisions in resource-limited settings. These
range from those employing the use of widely available blood
tests, such as aspartate transaminase (AST) to platelet ratio
(APRI) and potentially portable new technologies, such as
transient elastography (eg, FibroScan) [17]. These tests
generally perform well in distinguishing mild liver fibrosis
from advanced fibrosis and cirrhosis, but clinical decisions
for treatment often require the diagnosis of intermediate
stages of fibrosis and this limits the usefulness of such tests
[18]. Findings of a large European study suggest that the
FibroScan technique might be more useful than blood
markers [19]. Small, portable FibroScan units make the ap-
proach more feasible in resource-poor settings, but problems
with unreliable readings in inexperienced hands and main-
tenance of equipment create significant challenges.
The necessity of other investigations in the treatment of
HCV infection, in particular HCV viral load monitoring and
genotype tests, is an important consideration in planning
implementation of HCV treatment programs in resource-
limited and isolated settings. Increasing access to viral load
technology is becoming a priority within HIV/AIDS pro-
grams, and this could serve to benefit HCV programs [20].
Given the paucity of clinical findings in HCV infection before
end-stage disease with hepatic decompensation, the availability
of investigations may prove to be a larger hurdle for HCV
programs than it has been in the case of HIV. Finally, the relative
benefit of interleukin 28B testing, which is increasingly used to
help predict treatment response in Western settings, needs
careful consideration [21].
HCV program development can also learn from simplifi-
cation approaches to scaling up treatment for multidrug-
resistant tuberculosis. Multidrug-resistant tuberculosis care
requires frequent injections, multiple medications, and long
durations of treatment. Through models of care that pro-
vide psychosocial support and early recognition and man-
agement of adverse effects and through the decentralized
provision of care, good programmatic outcomes have been
achieved [22].
In the treatment of HIV infection, the introduction of less
toxic drugs and simplified, fixed-dose combinations has been
associated with improved adherence [23]. The arsenal of
HCV drugs is rapidly changing, and with recent data on
newer oral antiviral agents [24], interferon-free treatment
for HCV now seems achievable, offering the possibility of
injection-free treatment [25]. Mechanisms for accelerated
access to simplified treatment of HCV infection should be
prioritized.
The simplification agenda for HCV management will need
to take into account the different capacities of different settings.
Just as guidelines for ART specify a number of diagnostic tests
that, although not essential, are nevertheless highly desirable
[15], so recommendations for HCV management will need
to strike a balance between what can be done today and what
should be the standard for tomorrow.
TASK SHIFTING TO OVERCOME HUMAN
RESOURCE SHORTAGES
In developed countries, HIV/AIDS has conventionally been
managed by specialist physicians. However, health systems in
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resource-poor settings where the burden of HIV/AIDS is
greatest face a critical shortage of the most basic essential
health staff, with some high-burden countries having a 100-fold
fewer doctors per population compared with the United
Kingdom or United States [26]. To address this challenge, the
WHO published guidelines for task shifting, outlining a range of
tasks that could, with adequate training and supervision, be
delegated to nonphysician clinicians [27]. Randomized trials
and cohort studies have subsequently validated the safety and
effectiveness of task shifting for the provision of ART [28].
The decentralization of HCV management to lower levels of
the health system has been assessed in the United States as
a way to improve access to care. Outcomes of HCV treatment
provided at community settings with specialist supervision via
videoconference were found to be comparable to care pro-
vided at a dedicated HCV clinic in a tertiary center [29]. This
strategy will help to ensure that care is not limited by a lack of
specialists and the need to travel to tertiary level centers.
Operational research should be conducted to assess the po-
tential for different models of patient support and define the
appropriate skills mix for resource-limited settings.
SERVICE INTEGRATION
The provision of ART as a vertical (disease-specific) program
was an important early starting point in the AIDS response,
allowing for rapid establishment of services. As programs
expanded, integration of HIV/AIDS services into the broader
health system has become a priority [30]. Primary care serv-
ices in general, and clinics for antenatal care, tuberculosis, and
sexually transmitted infections in particular, have proved to
be important entry points for the diagnosis and treatment of
HIV, and integration of services has had an important in-
fluence on patient outcomes [31].
Similarly, for HCV services to reach larger numbers of
persons in a sustainable way, efforts will need to be made to
link HCV prevention and treatment services and integrate
treatment and care with other health services in which per-
sons at risk are likely to be identified and where provision of
quality of care is possible: needle syringe and oral sub-
stitution therapy programs, HIV clinics, and prison health
services. The first step would be to increase access to HCV
diagnostics in such services.
Integration of HIV management into general health
services has had mixed results, providing both positive and
negative lessons for HCV care [32]. The resulting literature
provides an important resource for HCV management pro-
grams. For example, a recent review of integration of HIV
and tuberculosis highlights some of the ways in which ver-
tical approaches have led to inefficient and ineffective pro-
gramming for both diseases [33].
SURVEILLANCE, EVALUATION, AND
RESEARCH
During the past decade, significant improvements in HIV
disease surveillance have informed service provision and
directed research. In contrast, there is a dearth of epidemiological
information regarding HCV infection rates in most parts of
the world [4]. Improved epidemiological information will
be critical in expanding HCV services, and many of the ap-
proaches developed to collect information about HIV in-
cidence and transmission could be adapted for use in HCV.
Increased information regarding the global scale and burden
of the epidemic in different settings will increase awareness
of the epidemic. Increased testing for HCV infection will be
an important component of accurate disease surveillance
and is also critical to treatment and prevention efforts [34].
This is particularly important because the development of
appropriate treatment strategies will require accurate in-
formation regarding genotype prevalence in different
countries.
The use of simplified reporting systems with standardized
indicators in ART programs has allowed regular monitoring
and the strategic direction of resources to improve service
provision through operational research [35]. In the develop-
ment of treatment programs for HCV infection, building in
methods of data collection and recording to allow regular and
routine program review will help facilitate ongoing service
feedback and improvement and will also help generate evi-
dence around the relative benefits and cost-effectiveness of
different program strategies.
The research and development agenda for HCV needs to
take better account of the specificities of resource-limited
countries. For HIV, factors such as heat stability of medi-
cations, minimal monitoring of drug regimens, and simpli-
fied drug dosing are important for simplifying care [36]. The
consideration of such factors in the process of drug de-
velopment for HCV could greatly facilitate the adoption of
treatments in resource-constrained settings.
PATIENT AND COMMUNITY ENGAGEMENT
In the scale-up of treatment for HIV infection, lack of patient
knowledge and stigma are understood to influence uptake of
testing and adherence to treatment. Efforts to tackle HIV
thus need to address both access to diagnosis and care, as
well as community education and stigma reduction com-
ponents [37]. Similarly, persons with HCV infection are
often not aware of their diagnosis or lack access to in-
formation about the benefits of treatment [38–41]. Efforts to
scale up HCV treatment must tackle community education
and stigma issues, especially among intravenous drug users.
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Initially, there was considerable concern about the challenge
of achieving adequate adherence to ART in resource-limited
settings, but reported rates of early adherence in sub-Saharan
Africa were found to be better than in North America [42].
Adherence counseling by patient experts or community health
workers has been demonstrated to be one of the most effective
ways of supporting patient adherence [43], while at the same
time relieving the burden on health workers. More recent
reviews have documented substantial attrition between di-
agnosis and initiation of ART, highlighting the need to de-
velop supportive models of care that start at the point of
diagnosis [44].
The treatment of HCV infection, like ART for HIV in-
fection, is associated with a range of adverse effects, many of
which are nonsevere but can lead to poor treatment adher-
ence. A recent meta-analysis of HCV program outcomes in
low- and middle-income settings found relatively low rates
of defaulting from care (4%) and low frequency of adverse
events leading to treatment discontinuation (4%) [3]. Nev-
ertheless, adherence support interventions for HCV treat-
ment need to be better defined, particularly as a proportion
of patients who will be eligible for treatment may be asymp-
tomatic. Treatment literacy programs to increase patients’
understanding of HCV disease and treatment, together with
dedicated peer support to assist with adherence and social
issues, will likely be an effective way to ensure that patients are
supported during the course of their treatment. Community
engagement in other areas of the care pathway such as testing
and screening have proved effective in scaling up access to
HIV care [45] and should also be explored for HCV.
The engagement of persons living with HIV has been ac-
knowledged as one of the most important achievements in the
AIDS response [46]. Persons living with HIV/AIDS have also
played a critical political role through activism to pressure
price reductions for antiretroviral drugs, increased funding,
and acceleration of research and development [47]. Similar
activism is beginning to take shape for HCV and will be
critical to making treatment more widely available [48].
ADDRESSING THE NEEDS OF VULNERABLE
GROUPS
From the outset, efforts to scale up ART in developing
countries have included a specific focus on such populations
who, because of oppression and vulnerability [49], have been
systematically excluded from access to treatment and care.
International reports mapping progress toward universal
access to prevention and treatment dedicate specific sections
to population groups, such as sex workers, injection drug
users, men who have sex with men, and prisoners [50], and
international funding mechanisms provide specific funding
for programs addressing the needs of vulnerable groups.
Given the high burden of HCV infection among injection
drug users [51], increased transmission risk in prisoners, and the
substantial overlap between the HIV and HCV epidemics, na-
tional and international efforts to support improved access to
HCV prevention, treatment, and care should benefit from the
positive experiences of expanding ART to vulnerable groups.
FINANCIAL AND POLITICAL COMMITMENT
The dramatic reduction in the cost of treatment was essential
to shifting the cost-effectiveness equation in favor of the
widespread provision of ART. In addition to increased bi-
lateral funding from a number of Western governments,
several international funding streams were established to
support ART scale-up, notably the Global Fund to Fight
AIDS, Tuberculosis, and Malaria (GFATM), and the US
President’s Emergency Plan for AIDS Relief [52].
To support an international effort to increase access to
treatment and care for HCV infection, dedicated funding
will be required to support the expansion of access to diag-
nostics and treatment and the promotion of operational
research to develop adapted models of care. The GFATM is
already providing some, albeit limited, funding for HCV
treatment for individuals coinfected with HCV and HIV, and
other donors, such as UNITAID, should explore how they
can support HCV care [53]. However, recent reductions in
donor contributions to GFATM threaten to limit the number
of programs that can be supported [54]. Political commit-
ment from the national governments of countries most af-
fected by HIV/AIDS has also been an essential driver of the
global response to HIV and will be critical in enabling the
provision of HCV treatment and care in institutions under
the management of correctional services.
CONCLUSIONS
Expanding access to hepatitis treatment in resource-limited
settings will require a dedicated effort to overcome practical
and political challenges. This also applies to care and treat-
ment for persons with hepatitis B virus infection [55], for
which many of the lessons outlined in this article apply.
Perhaps the most important lessons from the scaling up of
ART during the last decade is that this will not happen
without clear political commitment, and the engagement of
civil society to hold policy makers and drug manufacturers
to account. Recent demonstrations by activists in India to
call for reduced drug prices for hepatitis treatment could be
the first step toward reducing the present inequality where
hepatitis treatment and care are, for the most part, available
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only to patients who are fortunate enough to live in the
developed world.
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